Sponsor

Bannix Acquisition Corp. Announces Monthly Extension to Complete its Initial Business Combination

Retrieved on: 
Monday, March 18, 2024
Sponsor

WEST HOLLYWOOD, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Bannix Acquisition Corp. (“Bannix”) announced today that its board of directors (the “Board”) has decided to extend the date by which Bannix must consummate an initial business combination (the “Deadline Date”) from March 14, 2024 for an additional month, to April 14, 2024.

Key Points: 
  • WEST HOLLYWOOD, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Bannix Acquisition Corp. (“Bannix”) announced today that its board of directors (the “Board”) has decided to extend the date by which Bannix must consummate an initial business combination (the “Deadline Date”) from March 14, 2024 for an additional month, to April 14, 2024.
  • As previously disclosed, at an annual meeting of its stockholders held on March 8, 2024, Bannix’ stockholders voted in favor of a proposal to amend Bannix’s Amended and Restated Certificate of Incorporation (as amended, the “Amended Charter”) to provide Bannix with the right to extend the Deadline Date up to six times for an additional one month each time (the “Extension”) until September 14, 2024.
  • Also as previously announced, if an Extension is implemented, the sponsor of Bannix, Instant Fame LLC (the “Sponsor”), or its designees will deposit into the trust account, as a loan, the lesser of (x) $25,000 and (y) $0.05 for each share that is not redeemed in connection with the annual meeting.
  • On March 14, 2024, the Board, at the request of the Sponsor, decided to implement the thirteen Extension and to extend the Deadline Date for an additional month to April 14, 2024.

HIRERIGHT ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of HRT and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 16, 2024
HRT, Sponsor, Telephone, Acquisition, General Atlantic, P.C, Squire, Learning, HireRight

On February 16, 2024, HireRight announced that it had entered into an agreement to be acquired by the Sponsors in a $1.65 billion all-cash deal.

Key Points: 
  • On February 16, 2024, HireRight announced that it had entered into an agreement to be acquired by the Sponsors in a $1.65 billion all-cash deal.
  • Pursuant to the merger agreement, the Sponsors will acquire all of the outstanding shares they do not already own for $14.35 per share in cash.
  • Bragar Eagel & Squire is concerned that HireRight’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.
  • Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for HireRight’s stockholders.

Robbins LLP Reminds Investors that it is Investigating the Acquisition of HRT

Retrieved on: 
Tuesday, March 26, 2024
Class Action Lawsuit, Professional Services, Legal, Steps, HRT, Acquisition, General Atlantic, Sponsor, Proxy, HireRight, Security (finance)

Shareholder rights law firm Robbins LLP reminds investors it is investigating the acquisition of HireRight Holdings Corp. (NYSE: HRT) by investment funds affiliated with General Atlantic, L.P. and Stone Point Capital LLC (the "Sponsors").

Key Points: 
  • Shareholder rights law firm Robbins LLP reminds investors it is investigating the acquisition of HireRight Holdings Corp. (NYSE: HRT) by investment funds affiliated with General Atlantic, L.P. and Stone Point Capital LLC (the "Sponsors").
  • Is the Proposed Acquisition Best for HireRight Holdings Corp. (HRT) and its Shareholders?
  • Robbins LLP is concerned that HireRight's board of directors engaged in an unfair process and agreed to an unfair amount to be paid to shareholders.
  • Next Steps: If you own shares of HireRight Holdings Corp. (HRT) you have legal options.

Permianville Royalty Trust Announces Monthly Operational Update

Retrieved on: 
Monday, March 18, 2024
Oil, Gas, Energy, Sponsor, Trustee, Capital expenditure, Letter, Hand, Public expenditure, Bookkeeping

Total accrued operating expenses for the period were $2.5 million, a $0.3 million decrease month-over-month.

Key Points: 
  • Total accrued operating expenses for the period were $2.5 million, a $0.3 million decrease month-over-month.
  • Capital expenditures decreased $0.1 million from the prior period to $1.9 million.
  • The cumulative shortfall in net profits for the current month will be deducted from any net profits in next month’s net profits interest calculation.
  • The Trust will not receive proceeds pursuant to its net profits interest until the cumulative net profits shortfall is eliminated.

HRT Investor Notice: Robbins LLP Reminds Stockholders it is Investigating the Acquisition of HireRight Holdings Corp.

Retrieved on: 
Monday, March 18, 2024
Legal, Professional Services, Steps, HRT, Acquisition, General Atlantic, Sponsor, Proxy, HireRight, Security (finance)

Shareholder rights law firm Robbins LLP reminds investors it is investigating the acquisition of HireRight Holdings Corp. (NYSE: HRT) by investment funds affiliated with General Atlantic, L.P. and Stone Point Capital LLC (the "Sponsors").

Key Points: 
  • Shareholder rights law firm Robbins LLP reminds investors it is investigating the acquisition of HireRight Holdings Corp. (NYSE: HRT) by investment funds affiliated with General Atlantic, L.P. and Stone Point Capital LLC (the "Sponsors").
  • If you own shares of HireRight Holdings Corp. click here .
  • Is the Proposed Acquisition Best for HireRight Holdings Corp. (HRT) and its Shareholders?
  • Next Steps: If you own shares of HireRight Holdings Corp. (HRT) you have legal options.

Brex Inc. Closes Oversubscribed Third Securitization Issuance

Retrieved on: 
Wednesday, March 20, 2024
SAN, Jules Kroll, Note, AA, Sponsor, Bank

SAN FRANCISCO, March 20, 2024 /PRNewswire/ -- Brex, a leading AI-powered spend platform for modern companies, yesterday announced the closing of its third securitization transaction out of its previously established Brex Commercial Charge Card Master Trust.

Key Points: 
  • SAN FRANCISCO, March 20, 2024 /PRNewswire/ -- Brex , a leading AI-powered spend platform for modern companies, yesterday announced the closing of its third securitization transaction out of its previously established Brex Commercial Charge Card Master Trust.
  • The transaction included the issuance of $260M of charge card asset-based notes rated by Kroll Bond Rating Agency.
  • "Since our inaugural securitization issuance in 2021, the capital markets have recognized the low risk and stability of our customer base, which is manifested in this upgraded rating."
  • The accounts are opened through the Brex platform and ultimately approved and originated through Brex's partner bank relationships.

CoinShares strengthens its global reach by completing acquisition of Valkyrie ETF Business

Retrieved on: 
Tuesday, March 12, 2024
Bitcoin, WGMI, ETF, Trust, Acquisition, CS, AUM, Sponsor, BTF, Valkyrie, Cryptocurrency

CoinShares plans to rebrand Valkyrie as the Company's U.S. asset management platform that will concentrate on creating innovative products that stand out in the market.

Key Points: 
  • CoinShares plans to rebrand Valkyrie as the Company's U.S. asset management platform that will concentrate on creating innovative products that stand out in the market.
  • SAINT HELIER, Jersey, March 12, 2024 /PRNewswire/ -- CoinShares International Limited ("CoinShares" or "the Company") (Nasdaq Stockholm: CS; US OTCQX: CNSRF), the leading European investment company specialising in digital assets, today announced the completion of its acquisition of Valkyrie Funds LLC ("Valkyrie"), the investment advisory business of Valkyrie Investments Inc. ("Valkyrie Investments"), as well as the Sponsor rights to the Valkyrie Bitcoin Fund, the physically-backed Bitcoin ETF.
  • As previously announced, CoinShares has held an option to acquire Valkyrie since November 2023, which was exercised following Valkyrie Investments' launch of Valkyrie Bitcoin Fund in January 2024.
  • Looking ahead, CoinShares plans to use the Valkyrie ETF infrastructure to develop its U.S. asset management business, with a clear focus on product innovation and market differentiation.

Procedural advice for orphan medicinal product designation: Guidance for sponsors

Retrieved on: 
Wednesday, April 3, 2024
Community, Reproduction, Letter, European Commission, European Communities, Inn, Patient, Agency, Translation, European Medicines Agency, Council, European, Deference, VSI, Marketing, Legislation, Certification, MHLW, Annex, European Economic Area, PDF, Public, Medication, Committee, Policy, Bibliography, EMA, CAT, COMP, SME, Language, Ministry, CHMP, Decision, Cisco Webex, Prevalence, Disease, Part, Classification, Regulation (European Union), Privacy, Commission, RTF, EEA, Sponsor, PMDA, FDA, Guideline, Diagnosis, Civil service commission, European Council, European Parliament, Recognition, Art, INN, Official Journal, Record, TEAMS, Mutual, Microsoft PowerPoint, ID, Pharmaceutical industry

Frequently asked questions ................................................................... 10

Key Points: 
    • Frequently asked questions ................................................................... 10

      Procedural advice for orphan medicinal product designation
      EMA/420706/2018

      Page 2/13

      1.

    • This Regulation lays down the procedure for
      the designation of medicinal products as orphan medicinal products and provides incentives for the
      development and placing on the market of designated orphan medicinal products.
    • The Regulation also
      establishes the Committee for Orphan Medicinal Products (COMP) within the European Medicines
      Agency (EMA), which is responsible for examining applications for orphan medicinal product
      designation.
    • As of 28 April 2000, the date this Regulation entered into force, sponsors have been able to
      submit applications for orphan medicinal product designation to the EMA.
    • Procedural advice for orphan medicinal product designation
      EMA/420706/2018

      Page 3/13

      2.

    • Objectives
      In examining an application for orphan medicinal product designation, the COMP will focus on
      determining whether the sponsor has established that the designation criteria are met, i.e.
    • To assist in the development of a policy on orphan medicinal products, an expert network will
      be built up by the Committee, with expert(s) identified as appropriate to be involved in the evaluation
      of applications for orphan medicinal product designation.
    • ?

      The complete application should include:

      Procedural advice for orphan medicinal product designation
      EMA/420706/2018

      Page 5/13

      Document

      Format

      General administrative and scientific information completed online via the portal.

    • Important:
      In preparing an application for orphan medicinal product designation, sponsors are requested to follow
      the Commission guideline (2022/C 440/02) on the format and content of applications for designation
      as orphan medicinal products.
    • Please refer to the Procedural advice on
      appeal procedure for Orphan Medicinal Product Designation (EMEA/2677/01 Rev.3).
    • The grounds for the

      Procedural advice for orphan medicinal product designation
      EMA/420706/2018

      Page 9/13

      appeal should be based only on the original information provided in the application for orphan
      designation.

    • ?

      The European Commission will enter the designated medicinal product in the Community Register
      of Orphan Medicinal Products.

    • General advice
      ?

      Full information on the procedure for orphan medicinal products designation is available on the
      EMA orphan designation website.

    • In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the sponsor may submit an
      application for orphan medicinal product designation to the Agency at any stage of development of the

      Procedural advice for orphan medicinal product designation
      EMA/420706/2018

      Page 10/13

      medicinal product as long as the criteria for designation may be justified.

    • A request for orphan medicinal product designation may be made for
      a new orphan indication for an already authorised medicinal product.
    • Procedural advice for orphan medicinal product designation
      EMA/420706/2018

      Page 11/13

      Which are the sponsor?s options in case of negative outcome for orphan designation?

EudraVigilance registration manual

Retrieved on: 
Wednesday, April 3, 2024
Scroll, University, Data analysis, Patient, Account, Organization, MAH, Medicine, Manual, MFL, IAM, VAT, Finalize (optical discs), QAT, Competence, Documentation, Letter, Privacy, HQ2, ServiceNow, Environment, Trust (social science), RP, Table, Record, MPR, European Medicines Agency, Restricted area, Yahoo!, Identity management, Change request, Access, Qualified person (European Union), HQ, MMD, Home, Hospital, Research, Service, Network affiliate, Comment, Access management, OMS, Send, MSSO, ISO, Commercial, European, NCA, NCS, Managed services, Next, Document, EMA, PSMF, Language, MedDRA, AMP, Database, ICSR, Figure, EudraGMP, Dictionary, AMPS, Reproduction, Quality assurance, Identity, Virtual, Q2, SME, Change, Importance, Management, Security, Name, Location, Sponsor, Completeness, ID, 24 Hours, User, Vaccine
Key Points: 

    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), NGM Biopharmaceuticals, Inc. (Nasdaq – NGM), VIZIO Holding Corp. (NYSE - VZIO), HireRight Holdings Corporation (NYSE – HRT)

    Retrieved on: 
    Monday, February 26, 2024
    NGM, Shareholder, THL, Sponsor, Brodsky, General Atlantic, Walmart, Column, VIZIO, Thomas H. Lee Partners, HireRight, TCG, Security (finance)

    BALA CYNWYD, Pa., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.

    Key Points: 
    • BALA CYNWYD, Pa., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
    • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
    • Under the terms of the agreement, Agiliti will be acquired by Thomas H. Lee Partners, L.P. (“THL”).
    • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.